Mark Burton

Dr. Mark Burton

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2015 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
KSKristina P Sørensen
Kristina P Sørensen
MTMads Thomassen
Mads Thomassen
QTQihua Tan
Qihua Tan
MBMartin Bak
Martin Bak
SCSøren Cold
Søren Cold
TKTorben A. Kruse
Torben A. Kruse
Patients with clinically and pathologically similar breast tumors often have very different outcomes and treatment responses. Current prognostic markers allocate the majority of breast cancer patients to the high-risk group, yielding high sensitivities in expense of specificities below 20%, leading to considerable overtreatment, especially in lymph node-negative patients. Seventy percent would be cured by surgery and radiotherapy alone in this group. Thus, precise and early indicators of metastasis are highly desirable to reduce overtreatment. Previous prognostic RNA-profiling studies have only focused on the protein-coding part of the genome, however the human genome contains thousands of long non-coding RNAs (lncRNAs) and this unexplored field possesses large potential for identification of novel prognostic markers. We evaluated lncRNA microarray data from 164 primary breast tumors from adjuvant naïve patients with a mean follow-up of 18 years. Eighty two patients who developed detectable distant metastasis were compared to 82 patients where no metastases were diagnosed. For validation, we determined the prognostic value of the lncRNA profiles by comparing the ability of the profiles to predict metastasis in two additional, previously-published, cohorts. We showed that lncRNA profiles could distinguish metastatic patients from non-metastatic patients with sensitivities above 90% and specificities of 64-65%. Furthermore; classifications were independent of traditional prognostic markers and time to metastasis. To our knowledge, this is the first study investigating the prognostic potential of lncRNA profiles. Our study suggest that lncRNA profiles provide additional prognostic information and may contribute to the identification of early breast cancer patients eligible for adjuvant therapy, as well as early breast cancer patients that could avoid unnecessary systemic adjuvant therapy. This study emphasizes the potential role of lncRNAs in breast cancer prognosis.

25 April 2023 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
SLSoojung Lee
Soojung Lee
NTNicolai J. Toft
Nicolai J. Toft
TATrine V. Axelsen
Trine V. Axelsen
MEMaria Sofia Espejo
Maria Sofia Espejo
TPTina M. Pedersen
Tina M. Pedersen
EBEbbe Boedtkjer
Ebbe Boedtkjer
Background: Carbonic anhydrases catalyze CO2/HCO3– buffer reactions with implications for effective H+ mobility, pH dynamics, and cellular acid–base sensing. Yet, the integrated consequences of carbonic anhydrases for cancer and stromal cell functions, their interactions, and patient prognosis are not yet clear. Methods: We combine (a) bioinformatic analyses of human proteomic data and bulk and single-cell transcriptomic data coupled to clinicopathologic and prognostic information; (b) ex vivo experimental studies of gene expression in breast tissue based on quantitative reverse transcription and polymerase chain reactions, intracellular and extracellular pH recordings based on fluorescence confocal microscopy, and immunohistochemical protein identification in human and murine breast cancer biopsies; and (c) in vivo tumor size measurements, pH-sensitive microelectrode recordings, and microdialysis-based metabolite analyses in mice with experimentally induced breast carcinomas. Results: Carbonic anhydrases—particularly the extracellular isoforms CA4, CA6, CA9, CA12, and CA14—undergo potent expression changes during human and murine breast carcinogenesis. In patients with basal-like/triple-negative breast cancer, elevated expression of the extracellular carbonic anhydrases negatively predicts survival, whereas, surprisingly, the extracellular carbonic anhydrases positively predict patient survival in HER2/ErbB2-enriched breast cancer. Carbonic anhydrase inhibition attenuates cellular net acid extrusion and extracellular H+ elimination from diffusion-restricted to peripheral and well-perfused regions of human and murine breast cancer tissue. Supplied in vivo, the carbonic anhydrase inhibitor acetazolamide acidifies the microenvironment of ErbB2-induced murine breast carcinomas, limits tumor immune infiltration (CD3+ T cells, CD19+ B cells, F4/80+ macrophages), lowers inflammatory cytokine (Il1a, Il1b, Il6) and transcription factor (Nfkb1) expression, and accelerates tumor growth. Supporting the immunomodulatory influences of carbonic anhydrases, patient survival benefits associated with high extracellular carbonic anhydrase expression in HER2-enriched breast carcinomas depend on the tumor inflammatory profile. Acetazolamide lowers lactate levels in breast tissue and blood without influencing breast tumor perfusion, suggesting that carbonic anhydrase inhibition lowers fermentative glycolysis. Conclusions: We conclude that carbonic anhydrases (a) elevate pH in breast carcinomas by accelerating net H+ elimination from cancer cells and across the interstitial space and (b) raise immune infiltration and inflammation in ErbB2/HER2-driven breast carcinomas, restricting tumor growth and improving patient survival.

25 July 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SJStine Skov Jensen
Stine Skov Jensen
Morten MeyerMorten Meyer
Morten Meyer
SPStine Asferg Petterson
Stine Asferg Petterson
BHBo Halle
Bo Halle
ARAnn Mari Rosager
Ann Mari Rosager
BKBjarne Winther Kristensen
Bjarne Winther Kristensen
Glioblastoma is the most frequent and malignant brain tumor. Recurrence is inevitable and most likely connected to tumor invasion and presence of therapy resistant stem-like tumor cells. The aim was therefore to establish and characterize a three-dimensional in vivo-like in vitro model taking invasion and tumor stemness into account. Glioblastoma stem cell-like containing spheroid (GSS) cultures derived from three different patients were established and characterized. The spheroids were implanted in vitro into rat brain slice cultures grown in stem cell medium and in vivo into brains of immuno-compromised mice. Invasion was followed in the slice cultures by confocal time-lapse microscopy. Using immunohistochemistry, we compared tumor cell invasion as well as expression of proliferation and stem cell markers between the models. We observed a pronounced invasion into brain slice cultures both by confocal time-lapse microscopy and immunohistochemistry. This invasion closely resembled the invasion in vivo. The Ki-67 proliferation indexes in spheroids implanted into brain slices were lower than in free-floating spheroids. The expression of stem cell markers varied between free-floating spheroids, spheroids implanted into brain slices and tumors in vivo. The established invasion model kept in stem cell medium closely mimics tumor cell invasion into the brain in vivo preserving also to some extent the expression of stem cell markers. The model is feasible and robust and we suggest the model as an in vivo-like model with a great potential in glioma studies and drug discovery.

4 June 2025 in Circulation
Verified
Journal Article
Closed access
LOLasse M Obel
Lasse M Obel
JSJoachim Sejr Skovbo
Joachim Sejr Skovbo
ADAxel Cosmus Pyndt Diederichsen
Axel Cosmus Pyndt Diederichsen
MTmads Thomassen
mads Thomassen
LKLasse Kjær
Lasse Kjær
JLJes Sanddal Lindholt
Jes Sanddal Lindholt
BACKGROUND: The somatic JAK2 V617F sequence variation, a key driver of myeloproliferative neoplasms, has been associated with increased risk of aortic aneurysms. This study aimed to explore associations between the JAK2 V617F variant allele frequency (VAF) and ascending, descending, and abdominal aortic aneurysms. METHODS: In the DANCAVAS I and II trials (Danish Cardiovascular Screening), 15 000 individuals underwent cardiovascular risk assessments including blood samples and noncontrast ECG-gated computed tomography scans. In this cross-sectional substudy, individuals with screening-detected aortic aneurysms (≥45 mm ascending, ≥35 mm descending, or ≥30 mm abdominal), random aneurysm-free male controls, and all women (only included during the DANCAVAS I pilot study) were tested for the JAK2 V617F sequence variation. RESULTS: A total of 8056 individuals (90.9% men, mean age 68±4 years) were tested for the JAK2 V617F sequence variation, which presented an overall prevalence of 7.1%. Ascending, descending, and abdominal aneurysm prevalences were 6.6%, 2.9%, and 6.8%, respectively. In JAK2 V617F -negative participants (n=7486), JAK2 V617F -positive participants with VAF <1% (n=491), and JAK2 V617F -positive participants with VAF ≥1% (n=79), ascending aortic aneurysms were observed in 6.4%, 9.0%, and 16.5%, respectively ( P <0.001). No significant differences were observed across sequence variation groups for descending and abdominal aneurysms. Among JAK2 V617F -positive individuals, the median VAF was higher in those with ascending aneurysm (9.5%; interquartile range, 3.0–40.0) than in controls (4.4%; interquartile range, 1.8–20.0; P =0.021). Ascending aortic diameter correlated modestly with VAF (Spearman ρ=0.10; P =0.026). No significant correlations were observed for descending or abdominal diameters. For ascending aneurysms, JAK2 V617F VAF <1% and ≥1% presented adjusted odds ratios of 1.4 (95% CI, 1.01–2.0; P =0.045) and 2.7 (95% CI, 1.5–5.1; P =0.002), respectively, compared with JAK2 V617F -negative controls. For each doubling in VAF, the risk for ascending aneurysm increased by 11% ( P adjusted =0.013). The JAK2 V617F sequence variation was not significantly associated with descending or abdominal aneurysms after adjusting for covariates and using these VAF thresholds. CONCLUSIONS: In a study population of primarily men 60 to 74 years of age, the somatic JAK2 V617F sequence variation was strongly and independently associated with ascending aortic aneurysms, presenting a positive correlation between aneurysm size and JAK2 V617F VAF. No convincing associations were observed for descending or abdominal aneurysms. Screening patients with larger ascending aortic aneurysms for the JAK2 V617F sequence variation, and vice versa, screening JAK2 V617F -positve individuals presenting higher VAFs for ascending aneurysms, may be clinically appropriate.

Verified
Journal Article
Open access
PDF file
LMLine Aas Mortensen
Line Aas Mortensen
ASAnne Marie Svane
Anne Marie Svane
MBMark Burton
Mark Burton
CBClaus Bistrup
Claus Bistrup
HTHelle Charlotte Thiesson
Helle Charlotte Thiesson
HBHans Christian Beck
Hans Christian Beck
Renal transplantation is the preferred treatment of end stage renal disease, but allograft survival is limited by the development of interstitial fibrosis and tubular atrophy in response to various stimuli. Much effort has been put into identifying new protein markers of fibrosis to support the diagnosis. In the present work, we performed an in-depth quantitative proteomics analysis of allograft biopsies from 31 prevalent renal transplant patients and correlated the quantified proteins with the volume fraction of fibrosis as determined by a morphometric method. Linear regression analysis identified four proteins that were highly associated with the degree of interstitial fibrosis, namely Coagulation Factor XIII A chain (estimate 18.7, adjusted p < 0.03), Uridine Phosphorylase 1 (estimate 19.4, adjusted p < 0.001), Actin-related protein 2/3 subunit 2 (estimate 34.2, adjusted p < 0.05) and Cytochrome C Oxidase Assembly Factor 6 homolog (estimate −44.9, adjusted p < 0.002), even after multiple testing. Proteins that were negatively associated with fibrosis (p < 0.005) were primarily related to normal metabolic processes and respiration, whereas proteins that were positively associated with fibrosis (p < 0.005) were involved in catabolic processes, cytoskeleton organization and the immune response. The identified proteins may be candidates for further validation with regards to renal fibrosis. The results support the notion that cytoskeleton organization and immune responses are prevalent processes in renal allograft fibrosis.

29 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
NDnhu do
nhu do
IBInes Block
Ines Block
MBMark Burton
Mark Burton
KSKristina P. Sørensen
Kristina P. Sørensen
MLMartin Larsen
Martin Larsen
TKTorben A. Kruse
Torben A. Kruse
Several gene expression signatures based on mRNAs and a few based on long non-coding RNAs (lncRNAs) have been developed to provide prognostic information beyond clinical evaluation in breast cancer (BC). However, the comparison of such signatures for predicting recurrence is very scarce. Therefore, we compared the prognostic utility of mRNAs and lncRNAs in low-risk BC patients using two different classification strategies. Frozen primary tumor samples from 160 lymph node negative and systemically untreated BC patients were included; 80 developed recurrence—i.e., regional or distant metastasis while 80 remained recurrence-free (mean follow-up of 20.9 years). Patients were pairwise matched for clinicopathological characteristics. Classification based on differential mRNA or lncRNA expression using seven individual machine learning methods and a voting scheme classified patients into risk-subgroups. Classification by the seven methods with a fixed sensitivity of ≥90% resulted in specificities ranging from 16–40% for mRNA and 38–58% for lncRNA, and after voting, specificities of 38% and 60% respectively. Classifier performance based on an alternative classification approach of balanced accuracy optimization also provided higher specificities for lncRNA than mRNA at comparable sensitivities. Thus, our results suggested that classification followed by voting improved prognostic power using lncRNAs compared to mRNAs regardless of classification strategy.